Satralizumab monotherapy effective for seropositive NMOSD

This phase 3 study assessed the safety and efficacy of satralizumab monotherapy for neuromyelitis optica spectrum disorder (NMOSD).
Source: AAO

Posted in: Uncategorized

Leave a response

658 Malta Ave, Suite 101 Malta, NY 12020 (518) 580-0553